Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Alfred

Showing results (321-330 of 434) with videos related to

Pageof 44
Sort By:
BJU International|August 22, 2022
Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trialLeonie Exterkate, Olivier Wegelin, Jelle O Barentsz, et al.
AJR. American Journal of Roentgenology|June 24, 2015
Location of Prostate Cancers Determined by Multiparametric and MRI-Guided Biopsy in Patients With Elevated Prostate-Specific Antigen Level and at Least One Negative Transrectal Ultrasound-Guided BiopsyMartijn G Schouten, Caroline M A Hoeks, Joyce G R Bomers, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral ResectionErik Veskimae, Selvarani Subbarayan, Riccardo Campi, et al.
Investigative Radiology|October 16, 2004
Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostateJurgen J Fütterer, Tom W J Scheenen, Henkjan J Huisman, et al.
The Journal of Urology|September 6, 2006
Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker responseAntoine G van der Heijden, Paula M J Moonen, Erik B Cornel, et al.
EJNMMI Research|January 24, 2023
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementationSteffie M B Peters, Maaike C T Mink, Bastiaan M Privé, et al.
European Urology|September 30, 2019
Quality Indicators for Bladder Cancer Services: A Collaborative ReviewJeffrey J Leow, James W F Catto, Jason A Efstathiou, et al.
Urologic Oncology|April 18, 2022
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trialSiamak Daneshmand, Iris S G Brummelhuis, Kamal S Pohar, et al.
International Journal of Radiation Oncology, Biology, Physics|November 16, 2010
Magnetic resonance lymphography-guided selective high-dose lymph node irradiation in prostate cancerHanneke J M Meijer, Oscar A Debats, Martina Kunze-Busch, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 4, 2021
Intra-therapeutic dosimetry of [<sup>177</sup>Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcomeSteffie M B Peters, Bastiaan M Privé, Maarten de Bakker, et al.
Pageof 44

Showing results (321-330 of 434) with videos related to

Sort By:
Pageof 44
BJU International|August 22, 2022
Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trialLeonie Exterkate, Olivier Wegelin, Jelle O Barentsz, et al.
AJR. American Journal of Roentgenology|June 24, 2015
Location of Prostate Cancers Determined by Multiparametric and MRI-Guided Biopsy in Patients With Elevated Prostate-Specific Antigen Level and at Least One Negative Transrectal Ultrasound-Guided BiopsyMartijn G Schouten, Caroline M A Hoeks, Joyce G R Bomers, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral ResectionErik Veskimae, Selvarani Subbarayan, Riccardo Campi, et al.
Investigative Radiology|October 16, 2004
Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostateJurgen J Fütterer, Tom W J Scheenen, Henkjan J Huisman, et al.
The Journal of Urology|September 6, 2006
Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker responseAntoine G van der Heijden, Paula M J Moonen, Erik B Cornel, et al.
EJNMMI Research|January 24, 2023
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementationSteffie M B Peters, Maaike C T Mink, Bastiaan M Privé, et al.
European Urology|September 30, 2019
Quality Indicators for Bladder Cancer Services: A Collaborative ReviewJeffrey J Leow, James W F Catto, Jason A Efstathiou, et al.
Urologic Oncology|April 18, 2022
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trialSiamak Daneshmand, Iris S G Brummelhuis, Kamal S Pohar, et al.
International Journal of Radiation Oncology, Biology, Physics|November 16, 2010
Magnetic resonance lymphography-guided selective high-dose lymph node irradiation in prostate cancerHanneke J M Meijer, Oscar A Debats, Martina Kunze-Busch, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 4, 2021
Intra-therapeutic dosimetry of [<sup>177</sup>Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcomeSteffie M B Peters, Bastiaan M Privé, Maarten de Bakker, et al.
Pageof 44